Hypercholesterolemia

Two PCSK9 Inhibitors for LDL Cholesterol Promising in Studies

March 16, 2015

Evolocumab and alirocumab, monoclonal antibodies that inhibit proprotein convertase subtilisin-kexin type 9 (PCSK9), reduce low-density lipoprotein (LDL) cholesterol levels in the longer term, according to two studies published in the New England Journal of Medicine.